nodes	percent_of_prediction	percent_of_DWPC	metapath
Cytarabine—ABCC10—Cyclosporine—psoriasis	0.315	0.418	CbGbCtD
Cytarabine—ABCC10—Methotrexate—psoriasis	0.166	0.221	CbGbCtD
Cytarabine—CYP3A4—Calcitriol—psoriasis	0.0519	0.069	CbGbCtD
Cytarabine—CYP3A4—Methoxsalen—psoriasis	0.0403	0.0536	CbGbCtD
Cytarabine—CYP3A4—Cholecalciferol—psoriasis	0.0267	0.0355	CbGbCtD
Cytarabine—CYP3A4—Mycophenolate mofetil—psoriasis	0.0232	0.0308	CbGbCtD
Cytarabine—CYP3A4—Triamcinolone—psoriasis	0.0232	0.0308	CbGbCtD
Cytarabine—CYP3A4—Betamethasone—psoriasis	0.0199	0.0264	CbGbCtD
Cytarabine—CYP3A4—Prednisolone—psoriasis	0.0196	0.0261	CbGbCtD
Cytarabine—CYP3A4—Hydrocortisone—psoriasis	0.0186	0.0247	CbGbCtD
Cytarabine—CYP3A4—Prednisone—psoriasis	0.0185	0.0246	CbGbCtD
Cytarabine—CYP3A4—Cyclosporine—psoriasis	0.0176	0.0233	CbGbCtD
Cytarabine—CYP3A4—Dexamethasone—psoriasis	0.0116	0.0154	CbGbCtD
Cytarabine—NT5E—Purine catabolism—CAT—psoriasis	0.0108	0.0501	CbGpPWpGaD
Cytarabine—POLB—Removal of DNA patch containing abasic residue—PCNA—psoriasis	0.00903	0.0418	CbGpPWpGaD
Cytarabine—POLB—Base Excision Repair—PCNA—psoriasis	0.00826	0.0382	CbGpPWpGaD
Cytarabine—DCTD—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.00807	0.593	CbGdCrCtD
Cytarabine—POLD1—Mismatch repair—PCNA—psoriasis	0.00576	0.0266	CbGpPWpGaD
Cytarabine—Glucosamine—IFNG—psoriasis	0.00571	0.705	CrCbGaD
Cytarabine—POLD1—Removal of the Flap Intermediate from the C-strand—PCNA—psoriasis	0.00529	0.0245	CbGpPWpGaD
Cytarabine—POLD1—Processive synthesis on the C-strand of the telomere—PCNA—psoriasis	0.00457	0.0212	CbGpPWpGaD
Cytarabine—NT5E—Purine metabolism—CAT—psoriasis	0.00416	0.0193	CbGpPWpGaD
Cytarabine—NT5E—HIF-1-alpha transcription factor network—CP—psoriasis	0.00408	0.0189	CbGpPWpGaD
Cytarabine—POLD1—Removal of the Flap Intermediate—PCNA—psoriasis	0.00404	0.0187	CbGpPWpGaD
Cytarabine—POLD1—Leading Strand Synthesis—PCNA—psoriasis	0.00404	0.0187	CbGpPWpGaD
Cytarabine—POLD1—Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)—PCNA—psoriasis	0.00383	0.0177	CbGpPWpGaD
Cytarabine—POLD1—Repair synthesis for gap-filling by DNA polymerase in TC-NER—PCNA—psoriasis	0.00383	0.0177	CbGpPWpGaD
Cytarabine—POLD1—Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)—PCNA—psoriasis	0.00383	0.0177	CbGpPWpGaD
Cytarabine—POLE—Repair synthesis for gap-filling by DNA polymerase in TC-NER—PCNA—psoriasis	0.00369	0.0171	CbGpPWpGaD
Cytarabine—DCTD—Nucleotide metabolism—CAT—psoriasis	0.00364	0.0169	CbGpPWpGaD
Cytarabine—POLD1—MMR—PCNA—psoriasis	0.00363	0.0168	CbGpPWpGaD
Cytarabine—POLD1—Processive synthesis on the lagging strand—PCNA—psoriasis	0.00363	0.0168	CbGpPWpGaD
Cytarabine—POLD1—Gap-filling DNA repair synthesis and ligation in GG-NER—PCNA—psoriasis	0.00346	0.016	CbGpPWpGaD
Cytarabine—POLD1—Removal of DNA patch containing abasic residue—PCNA—psoriasis	0.00346	0.016	CbGpPWpGaD
Cytarabine—POLE—Gap-filling DNA repair synthesis and ligation in GG-NER—PCNA—psoriasis	0.00334	0.0155	CbGpPWpGaD
Cytarabine—POLD1—Base Excision Repair—PCNA—psoriasis	0.00317	0.0147	CbGpPWpGaD
Cytarabine—POLD1—Lagging Strand Synthesis—PCNA—psoriasis	0.00292	0.0135	CbGpPWpGaD
Cytarabine—POLA1—Removal of the Flap Intermediate—PCNA—psoriasis	0.00278	0.0129	CbGpPWpGaD
Cytarabine—POLA1—Leading Strand Synthesis—PCNA—psoriasis	0.00278	0.0129	CbGpPWpGaD
Cytarabine—POLD1—Telomere C-strand (Lagging Strand) Synthesis—PCNA—psoriasis	0.00272	0.0126	CbGpPWpGaD
Cytarabine—POLE—Telomere C-strand (Lagging Strand) Synthesis—PCNA—psoriasis	0.00262	0.0121	CbGpPWpGaD
Cytarabine—POLA1—Processive synthesis on the lagging strand—PCNA—psoriasis	0.0025	0.0116	CbGpPWpGaD
Cytarabine—Glucosamine—TNF—psoriasis	0.00239	0.295	CrCbGaD
Cytarabine—POLA1—G1/S-Specific Transcription—PCNA—psoriasis	0.00238	0.011	CbGpPWpGaD
Cytarabine—POLD1—Extension of Telomeres—PCNA—psoriasis	0.00226	0.0104	CbGpPWpGaD
Cytarabine—DCK—Purine metabolism—CAT—psoriasis	0.00222	0.0103	CbGpPWpGaD
Cytarabine—POLE—Extension of Telomeres—PCNA—psoriasis	0.00218	0.0101	CbGpPWpGaD
Cytarabine—NT5E—Nucleotide metabolism—CAT—psoriasis	0.00209	0.00968	CbGpPWpGaD
Cytarabine—POLD1—DNA strand elongation—PCNA—psoriasis	0.00209	0.00966	CbGpPWpGaD
Cytarabine—POLA1—Lagging Strand Synthesis—PCNA—psoriasis	0.00201	0.00931	CbGpPWpGaD
Cytarabine—POLD1—Global Genomic NER (GG-NER)—PCNA—psoriasis	0.00199	0.0092	CbGpPWpGaD
Cytarabine—POLB—DNA Repair—PCNA—psoriasis	0.00198	0.00918	CbGpPWpGaD
Cytarabine—POLE—Global Genomic NER (GG-NER)—PCNA—psoriasis	0.00192	0.00889	CbGpPWpGaD
Cytarabine—CDA—Nucleotide metabolism—CAT—psoriasis	0.00191	0.00886	CbGpPWpGaD
Cytarabine—POLA1—Telomere C-strand (Lagging Strand) Synthesis—PCNA—psoriasis	0.00187	0.00866	CbGpPWpGaD
Cytarabine—NT5E—HIF-1-alpha transcription factor network—LEP—psoriasis	0.00186	0.0086	CbGpPWpGaD
Cytarabine—POLB—skin of body—psoriasis	0.00177	0.176	CbGeAlD
Cytarabine—NT5E—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.00173	0.00801	CbGpPWpGaD
Cytarabine—POLD1—DNA Replication—PCNA—psoriasis	0.00168	0.00777	CbGpPWpGaD
Cytarabine—POLE—DNA Replication—PCNA—psoriasis	0.00162	0.0075	CbGpPWpGaD
Cytarabine—POLD1—Transcription-coupled NER (TC-NER)—PCNA—psoriasis	0.00159	0.00735	CbGpPWpGaD
Cytarabine—POLA1—Extension of Telomeres—PCNA—psoriasis	0.00155	0.00719	CbGpPWpGaD
Cytarabine—POLE—Transcription-coupled NER (TC-NER)—PCNA—psoriasis	0.00153	0.0071	CbGpPWpGaD
Cytarabine—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.00147	0.00681	CbGpPWpGaD
Cytarabine—POLD1—Nucleotide Excision Repair—PCNA—psoriasis	0.00146	0.00676	CbGpPWpGaD
Cytarabine—POLD1—skin of body—psoriasis	0.00145	0.143	CbGeAlD
Cytarabine—POLA1—DNA strand elongation—PCNA—psoriasis	0.00144	0.00665	CbGpPWpGaD
Cytarabine—POLE—Nucleotide Excision Repair—PCNA—psoriasis	0.00141	0.00653	CbGpPWpGaD
Cytarabine—POLA1—E2F mediated regulation of DNA replication—PCNA—psoriasis	0.0014	0.00648	CbGpPWpGaD
Cytarabine—DCTD—Metabolism—NDUFA5—psoriasis	0.0013	0.006	CbGpPWpGaD
Cytarabine—NT5E—Differentiation Pathway—VEGFA—psoriasis	0.00129	0.00599	CbGpPWpGaD
Cytarabine—CDA—Fluoropyrimidine Activity—TP53—psoriasis	0.00121	0.00559	CbGpPWpGaD
Cytarabine—POLA1—DNA Replication—PCNA—psoriasis	0.00116	0.00535	CbGpPWpGaD
Cytarabine—NT5E—HIF-1-alpha transcription factor network—JUN—psoriasis	0.00115	0.00531	CbGpPWpGaD
Cytarabine—DCK—Nucleotide metabolism—CAT—psoriasis	0.00112	0.00517	CbGpPWpGaD
Cytarabine—NT5E—skin of body—psoriasis	0.0011	0.109	CbGeAlD
Cytarabine—POLE—G1 to S cell cycle control—PCNA—psoriasis	0.0011	0.0051	CbGpPWpGaD
Cytarabine—DCTD—Metabolism—CYP2S1—psoriasis	0.0011	0.0051	CbGpPWpGaD
Cytarabine—DCTD—tendon—psoriasis	0.00109	0.108	CbGeAlD
Cytarabine—POLD1—Telomere Maintenance—PCNA—psoriasis	0.00102	0.00473	CbGpPWpGaD
Cytarabine—NT5E—HIF-1-alpha transcription factor network—VEGFA—psoriasis	0.001	0.00464	CbGpPWpGaD
Cytarabine—CDA—tendon—psoriasis	0.000989	0.098	CbGeAlD
Cytarabine—POLE—Telomere Maintenance—PCNA—psoriasis	0.000988	0.00457	CbGpPWpGaD
Cytarabine—POLE—Retinoblastoma (RB) in Cancer—PCNA—psoriasis	0.000905	0.00419	CbGpPWpGaD
Cytarabine—NT5E—Differentiation Pathway—IL6—psoriasis	0.000895	0.00414	CbGpPWpGaD
Cytarabine—DCK—Retinoblastoma (RB) in Cancer—PCNA—psoriasis	0.000881	0.00408	CbGpPWpGaD
Cytarabine—POLD1—Synthesis of DNA—PCNA—psoriasis	0.000867	0.00401	CbGpPWpGaD
Cytarabine—SLC29A1—SLC-mediated transmembrane transport—CP—psoriasis	0.000863	0.00399	CbGpPWpGaD
Cytarabine—POLD1—Chromosome Maintenance—PCNA—psoriasis	0.000852	0.00394	CbGpPWpGaD
Cytarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000844	0.0039	CbGpPWpGaD
Cytarabine—NT5E—tendon—psoriasis	0.000841	0.0833	CbGeAlD
Cytarabine—POLE—Synthesis of DNA—PCNA—psoriasis	0.000837	0.00387	CbGpPWpGaD
Cytarabine—SLC29A1—Fluoropyrimidine Activity—TP53—psoriasis	0.000837	0.00387	CbGpPWpGaD
Cytarabine—POLE—tendon—psoriasis	0.000824	0.0816	CbGeAlD
Cytarabine—POLE—Chromosome Maintenance—PCNA—psoriasis	0.000823	0.00381	CbGpPWpGaD
Cytarabine—POLD1—DNA Replication—PCNA—psoriasis	0.000813	0.00376	CbGpPWpGaD
Cytarabine—POLE—DNA Replication—PCNA—psoriasis	0.000785	0.00363	CbGpPWpGaD
Cytarabine—POLE—Mitotic M-M/G1 phases—PTTG1—psoriasis	0.000766	0.00355	CbGpPWpGaD
Cytarabine—POLD1—DNA Repair—PCNA—psoriasis	0.000761	0.00352	CbGpPWpGaD
Cytarabine—POLE—G1/S Transition—PCNA—psoriasis	0.000756	0.0035	CbGpPWpGaD
Cytarabine—NT5E—Metabolism—NDUFA5—psoriasis	0.000744	0.00344	CbGpPWpGaD
Cytarabine—POLE—DNA Repair—PCNA—psoriasis	0.000735	0.0034	CbGpPWpGaD
Cytarabine—POLD1—S Phase—PCNA—psoriasis	0.000711	0.00329	CbGpPWpGaD
Cytarabine—POLA1—tendon—psoriasis	0.00071	0.0704	CbGeAlD
Cytarabine—POLA1—Telomere Maintenance—PCNA—psoriasis	0.000704	0.00326	CbGpPWpGaD
Cytarabine—POLE—S Phase—PCNA—psoriasis	0.000686	0.00318	CbGpPWpGaD
Cytarabine—CDA—Metabolism—NDUFA5—psoriasis	0.000681	0.00315	CbGpPWpGaD
Cytarabine—POLA1—Retinoblastoma (RB) in Cancer—PCNA—psoriasis	0.000645	0.00299	CbGpPWpGaD
Cytarabine—POLE—Mitotic G1-G1/S phases—PCNA—psoriasis	0.000637	0.00295	CbGpPWpGaD
Cytarabine—NT5E—Metabolism—CYP2S1—psoriasis	0.000633	0.00293	CbGpPWpGaD
Cytarabine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000633	0.00293	CbGpPWpGaD
Cytarabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000611	0.00283	CbGpPWpGaD
Cytarabine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000603	0.00279	CbGpPWpGaD
Cytarabine—POLA1—Synthesis of DNA—PCNA—psoriasis	0.000596	0.00276	CbGpPWpGaD
Cytarabine—POLD1—Cell Cycle, Mitotic—PTTG1—psoriasis	0.000594	0.00275	CbGpPWpGaD
Cytarabine—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.00059	0.00273	CbGpPWpGaD
Cytarabine—POLA1—Chromosome Maintenance—PCNA—psoriasis	0.000587	0.00271	CbGpPWpGaD
Cytarabine—CDA—Metabolism—CYP2S1—psoriasis	0.000579	0.00268	CbGpPWpGaD
Cytarabine—POLE—Cell Cycle, Mitotic—PTTG1—psoriasis	0.000573	0.00265	CbGpPWpGaD
Cytarabine—POLA1—DNA Replication—PCNA—psoriasis	0.000559	0.00259	CbGpPWpGaD
Cytarabine—ABCC10—Transmembrane transport of small molecules—CP—psoriasis	0.000553	0.00256	CbGpPWpGaD
Cytarabine—POLA1—Mitotic M-M/G1 phases—PTTG1—psoriasis	0.000546	0.00253	CbGpPWpGaD
Cytarabine—POLA1—G1/S Transition—PCNA—psoriasis	0.000539	0.00249	CbGpPWpGaD
Cytarabine—DCTD—Metabolism—CARM1—psoriasis	0.000538	0.00249	CbGpPWpGaD
Cytarabine—POLD1—Cell Cycle—PTTG1—psoriasis	0.000531	0.00246	CbGpPWpGaD
Cytarabine—ABCC10—Transmembrane transport of small molecules—CARM1—psoriasis	0.000528	0.00244	CbGpPWpGaD
Cytarabine—POLE—Cell Cycle—PTTG1—psoriasis	0.000513	0.00237	CbGpPWpGaD
Cytarabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000495	0.00229	CbGpPWpGaD
Cytarabine—POLA1—S Phase—PCNA—psoriasis	0.000489	0.00226	CbGpPWpGaD
Cytarabine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000489	0.00226	CbGpPWpGaD
Cytarabine—SLC29A1—tendon—psoriasis	0.000458	0.0454	CbGeAlD
Cytarabine—POLA1—Mitotic G1-G1/S phases—PCNA—psoriasis	0.000454	0.0021	CbGpPWpGaD
Cytarabine—POLD1—Danazol—Hydrocortisone—psoriasis	0.000446	0.0327	CbGdCrCtD
Cytarabine—SLC29A1—Transmembrane transport of small molecules—CP—psoriasis	0.000439	0.00203	CbGpPWpGaD
Cytarabine—DCK—tendon—psoriasis	0.000438	0.0434	CbGeAlD
Cytarabine—POLD1—Metabolism—NDUFA5—psoriasis	0.000422	0.00195	CbGpPWpGaD
Cytarabine—SLC29A1—Transmembrane transport of small molecules—CARM1—psoriasis	0.000418	0.00194	CbGpPWpGaD
Cytarabine—ABCC10—tendon—psoriasis	0.000417	0.0413	CbGeAlD
Cytarabine—POLA1—Cell Cycle, Mitotic—PTTG1—psoriasis	0.000408	0.00189	CbGpPWpGaD
Cytarabine—POLE—G1 to S cell cycle control—TP53—psoriasis	0.000405	0.00188	CbGpPWpGaD
Cytarabine—DCK—Metabolism—NDUFA5—psoriasis	0.000397	0.00184	CbGpPWpGaD
Cytarabine—DCK—Desoximetasone—Clobetasol propionate—psoriasis	0.000393	0.0289	CbGdCrCtD
Cytarabine—POLD1—Danazol—Prednisone—psoriasis	0.000384	0.0282	CbGdCrCtD
Cytarabine—DCK—Diflorasone—Clobetasol propionate—psoriasis	0.000381	0.028	CbGdCrCtD
Cytarabine—POLA1—Cell Cycle—PTTG1—psoriasis	0.000365	0.00169	CbGpPWpGaD
Cytarabine—POLD1—Metabolism—CYP2S1—psoriasis	0.000359	0.00166	CbGpPWpGaD
Cytarabine—POLA1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.000344	0.00159	CbGpPWpGaD
Cytarabine—DCK—Metabolism—CYP2S1—psoriasis	0.000338	0.00156	CbGpPWpGaD
Cytarabine—POLE—Retinoblastoma (RB) in Cancer—TP53—psoriasis	0.000333	0.00154	CbGpPWpGaD
Cytarabine—DCTD—Metabolism—CAT—psoriasis	0.000331	0.00153	CbGpPWpGaD
Cytarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—psoriasis	0.000324	0.0015	CbGpPWpGaD
Cytarabine—DCK—Desoximetasone—Beclomethasone—psoriasis	0.000315	0.0231	CbGdCrCtD
Cytarabine—DCK—Desoximetasone—Fluocinonide—psoriasis	0.000315	0.0231	CbGdCrCtD
Cytarabine—NT5E—Metabolism—CARM1—psoriasis	0.000309	0.00143	CbGpPWpGaD
Cytarabine—DCK—Desoximetasone—Fluocinolone Acetonide—psoriasis	0.000306	0.0225	CbGdCrCtD
Cytarabine—DCK—Diflorasone—Beclomethasone—psoriasis	0.000305	0.0224	CbGdCrCtD
Cytarabine—DCK—Diflorasone—Fluocinonide—psoriasis	0.000305	0.0224	CbGdCrCtD
Cytarabine—DCK—Diflorasone—Fluocinolone Acetonide—psoriasis	0.000297	0.0218	CbGdCrCtD
Cytarabine—POLA1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	0.000289	0.00134	CbGpPWpGaD
Cytarabine—SLC22A2—SLC-mediated transmembrane transport—CP—psoriasis	0.000288	0.00133	CbGpPWpGaD
Cytarabine—CDA—Metabolism—CARM1—psoriasis	0.000283	0.00131	CbGpPWpGaD
Cytarabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000281	0.0013	CbGpPWpGaD
Cytarabine—POLA1—Norethindrone—Hydrocortisone—psoriasis	0.000275	0.0202	CbGdCrCtD
Cytarabine—SLC22A1—SLC-mediated transmembrane transport—CP—psoriasis	0.000268	0.00124	CbGpPWpGaD
Cytarabine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000263	0.00122	CbGpPWpGaD
Cytarabine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.00026	0.0012	CbGpPWpGaD
Cytarabine—DCTD—Metabolism—APOE—psoriasis	0.000257	0.00119	CbGpPWpGaD
Cytarabine—POLD1—Cell Cycle, Mitotic—PCNA—psoriasis	0.000242	0.00112	CbGpPWpGaD
Cytarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—psoriasis	0.000237	0.0011	CbGpPWpGaD
Cytarabine—POLE—Cell Cycle, Mitotic—PCNA—psoriasis	0.000234	0.00108	CbGpPWpGaD
Cytarabine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000227	0.00105	CbGpPWpGaD
Cytarabine—DCTD—Metabolism—PPARG—psoriasis	0.000224	0.00104	CbGpPWpGaD
Cytarabine—POLA1—Levonorgestrel—Hydrocortisone—psoriasis	0.000219	0.0161	CbGdCrCtD
Cytarabine—POLD1—Cell Cycle—PCNA—psoriasis	0.000216	0.001	CbGpPWpGaD
Cytarabine—POLE—Cell Cycle—PCNA—psoriasis	0.000209	0.000967	CbGpPWpGaD
Cytarabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000196	0.000906	CbGpPWpGaD
Cytarabine—POLA1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	0.000192	0.000887	CbGpPWpGaD
Cytarabine—NT5E—Metabolism—CAT—psoriasis	0.00019	0.00088	CbGpPWpGaD
Cytarabine—POLA1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	0.000184	0.000853	CbGpPWpGaD
Cytarabine—POLD1—Metabolism—CARM1—psoriasis	0.000175	0.000811	CbGpPWpGaD
Cytarabine—CDA—Metabolism—CAT—psoriasis	0.000174	0.000805	CbGpPWpGaD
Cytarabine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	0.000167	0.000775	CbGpPWpGaD
Cytarabine—POLA1—Cell Cycle, Mitotic—PCNA—psoriasis	0.000166	0.00077	CbGpPWpGaD
Cytarabine—DCK—Metabolism—CARM1—psoriasis	0.000165	0.000763	CbGpPWpGaD
Cytarabine—SLC22A2—Metabolism—NDUFA5—psoriasis	0.000157	0.000728	CbGpPWpGaD
Cytarabine—DCK—Desoximetasone—Hydrocortisone—psoriasis	0.000154	0.0113	CbGdCrCtD
Cytarabine—POLA1—Cell Cycle—PCNA—psoriasis	0.000149	0.000689	CbGpPWpGaD
Cytarabine—NT5E—Metabolism—APOE—psoriasis	0.000148	0.000684	CbGpPWpGaD
Cytarabine—SLC22A1—Metabolism—NDUFA5—psoriasis	0.000147	0.000678	CbGpPWpGaD
Cytarabine—SLC22A2—Transmembrane transport of small molecules—CP—psoriasis	0.000146	0.000676	CbGpPWpGaD
Cytarabine—DCK—Desoximetasone—Betamethasone—psoriasis	0.000143	0.0105	CbGdCrCtD
Cytarabine—DCK—Desoximetasone—Dexamethasone—psoriasis	0.000143	0.0105	CbGdCrCtD
Cytarabine—POLA1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	0.000143	0.000664	CbGpPWpGaD
Cytarabine—DCK—Desoximetasone—Triamcinolone—psoriasis	0.00014	0.0103	CbGdCrCtD
Cytarabine—SLC22A2—Transmembrane transport of small molecules—CARM1—psoriasis	0.000139	0.000645	CbGpPWpGaD
Cytarabine—DCK—Diflorasone—Betamethasone—psoriasis	0.000139	0.0102	CbGdCrCtD
Cytarabine—DCK—Diflorasone—Dexamethasone—psoriasis	0.000139	0.0102	CbGdCrCtD
Cytarabine—SLC22A1—Transmembrane transport of small molecules—CP—psoriasis	0.000136	0.00063	CbGpPWpGaD
Cytarabine—DCK—Diflorasone—Triamcinolone—psoriasis	0.000136	0.00999	CbGdCrCtD
Cytarabine—CDA—Metabolism—APOE—psoriasis	0.000135	0.000625	CbGpPWpGaD
Cytarabine—SLC22A2—Metabolism—CYP2S1—psoriasis	0.000134	0.000619	CbGpPWpGaD
Cytarabine—DCK—Desoximetasone—Prednisone—psoriasis	0.000133	0.00977	CbGdCrCtD
Cytarabine—SLC22A1—Transmembrane transport of small molecules—CARM1—psoriasis	0.00013	0.000601	CbGpPWpGaD
Cytarabine—DCK—Desoximetasone—Prednisolone—psoriasis	0.00013	0.00953	CbGdCrCtD
Cytarabine—DCK—Diflorasone—Prednisone—psoriasis	0.000129	0.00948	CbGdCrCtD
Cytarabine—NT5E—Metabolism—PPARG—psoriasis	0.000129	0.000595	CbGpPWpGaD
Cytarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	0.000126	0.000585	CbGpPWpGaD
Cytarabine—DCK—Diflorasone—Prednisolone—psoriasis	0.000126	0.00925	CbGdCrCtD
Cytarabine—SLC22A1—Metabolism—CYP2S1—psoriasis	0.000125	0.000577	CbGpPWpGaD
Cytarabine—CDA—Metabolism—PPARG—psoriasis	0.000118	0.000545	CbGpPWpGaD
Cytarabine—POLD1—Metabolism—CAT—psoriasis	0.000108	0.000499	CbGpPWpGaD
Cytarabine—DCK—Metabolism—CAT—psoriasis	0.000101	0.000469	CbGpPWpGaD
Cytarabine—DCK—Levonorgestrel—Hydrocortisone—psoriasis	9.03e-05	0.00663	CbGdCrCtD
Cytarabine—POLD1—Metabolism—APOE—psoriasis	8.38e-05	0.000388	CbGpPWpGaD
Cytarabine—POLD1—Cell Cycle—TP53—psoriasis	7.95e-05	0.000368	CbGpPWpGaD
Cytarabine—DCK—Metabolism—APOE—psoriasis	7.88e-05	0.000365	CbGpPWpGaD
Cytarabine—POLE—Cell Cycle—TP53—psoriasis	7.68e-05	0.000356	CbGpPWpGaD
Cytarabine—POLD1—Metabolism—PPARG—psoriasis	7.3e-05	0.000338	CbGpPWpGaD
Cytarabine—DCK—Metabolism—PPARG—psoriasis	6.86e-05	0.000318	CbGpPWpGaD
Cytarabine—SLC22A2—Metabolism—CARM1—psoriasis	6.53e-05	0.000302	CbGpPWpGaD
Cytarabine—SLC22A1—Metabolism—CARM1—psoriasis	6.09e-05	0.000282	CbGpPWpGaD
Cytarabine—POLA1—Cell Cycle—TP53—psoriasis	5.47e-05	0.000253	CbGpPWpGaD
Cytarabine—CYP3A4—Metabolism—NDUFA5—psoriasis	5.29e-05	0.000245	CbGpPWpGaD
Cytarabine—CYP3A4—Metabolism—CYP2S1—psoriasis	4.5e-05	0.000208	CbGpPWpGaD
Cytarabine—SLC22A2—Metabolism—CAT—psoriasis	4.02e-05	0.000186	CbGpPWpGaD
Cytarabine—SLC22A1—Metabolism—CAT—psoriasis	3.74e-05	0.000173	CbGpPWpGaD
Cytarabine—SLC22A2—Metabolism—APOE—psoriasis	3.12e-05	0.000144	CbGpPWpGaD
Cytarabine—SLC22A1—Metabolism—APOE—psoriasis	2.91e-05	0.000135	CbGpPWpGaD
Cytarabine—SLC22A2—Metabolism—PPARG—psoriasis	2.72e-05	0.000126	CbGpPWpGaD
Cytarabine—SLC22A1—Metabolism—PPARG—psoriasis	2.53e-05	0.000117	CbGpPWpGaD
Cytarabine—CYP3A4—Metabolism—CARM1—psoriasis	2.2e-05	0.000102	CbGpPWpGaD
Cytarabine—CYP3A4—Metabolism—CAT—psoriasis	1.35e-05	6.26e-05	CbGpPWpGaD
Cytarabine—CYP3A4—Metabolism—APOE—psoriasis	1.05e-05	4.86e-05	CbGpPWpGaD
Cytarabine—CYP3A4—Metabolism—PPARG—psoriasis	9.15e-06	4.23e-05	CbGpPWpGaD
